Company Overview

Integrated Biopharma, Inc. is a nutraceutical and pharmaceutical contract manufacturing company that operates primarily in the dietary supplements, vitamins, and nutritional products industries. The company focuses on the development, manufacturing, and distribution of health and wellness products for branded customers, private-label clients, and its own proprietary brands. Revenue is primarily generated through manufacturing services and finished product sales to distributors, retailers, and direct customers in regulated consumer health markets.

The company’s business model emphasizes in-house manufacturing, regulatory compliance, and formulation capabilities, which allow it to serve customers seeking turnkey supplement production. Integrated Biopharma evolved from a contract manufacturing focus into a vertically integrated operator with branded offerings, expanding its role across product development, production, and limited distribution. Public disclosures indicate the company has operated as a small-cap public entity for multiple decades, with its shares quoted under the ticker INBP.

Business Operations

Integrated Biopharma conducts operations primarily through its nutraceutical manufacturing and distribution activities, with revenue derived from contract manufacturing services, private-label production, and sales of proprietary supplement products. Its operations include formulation, blending, encapsulation, tableting, and packaging of dietary supplements and related products, serving customers that range from emerging supplement brands to established marketers.

The company operates through subsidiaries including Manhattan Drug Company, Inc., which functions as a core manufacturing and product development unit. Integrated Biopharma maintains manufacturing facilities and quality control systems designed to comply with U.S. dietary supplement regulations, and it relies on long-term customer relationships rather than large-scale consumer marketing for revenue stability. Public information on joint ventures or strategic partnerships is limited, and no material joint ventures have been consistently disclosed.

Strategic Position & Investments

Integrated Biopharma’s strategic direction centers on maintaining manufacturing utilization, expanding private-label and contract manufacturing relationships, and selectively growing proprietary product lines. The company has historically emphasized operational efficiency, regulatory compliance, and customer retention rather than aggressive acquisition-driven growth.

Reported investments have primarily involved internal manufacturing capabilities, quality systems, and working capital support for customer programs. While the company has disclosed ownership of subsidiaries aligned with manufacturing and branded nutraceuticals, publicly available filings do not indicate significant recent acquisitions or material investments in emerging biotechnology platforms. Data inconclusive based on available public sources regarding involvement in advanced biopharmaceutical technologies beyond nutraceuticals.

Geographic Footprint

Integrated Biopharma’s operations are primarily concentrated in the United States, where its manufacturing facilities, corporate functions, and regulatory activities are based. The company serves domestic customers across multiple states and participates in interstate distribution of dietary supplements and health products.

International exposure is indirect and limited, generally occurring through customers that distribute finished products outside the U.S. Public disclosures do not indicate the presence of owned manufacturing facilities or offices outside the United States, nor significant foreign capital investments.

Leadership & Governance

Integrated Biopharma is led by an executive team with experience in nutraceutical manufacturing, operations, and regulatory compliance. Governance follows the structure of a U.S. public company, with oversight provided by a board of directors and executive management responsible for operational execution and financial reporting.

• Chaim Z. Friedman – President and Chief Executive Officer
• Eyal Barad – Chief Financial Officer

Public filings consistently identify senior executive leadership; however, detailed disclosures on broader executive management and leadership philosophy are limited. Data inconclusive based on available public sources regarding additional named executive officers beyond those listed above.